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To the Editor:  
The seroprevalence of human cytomegalovirus (CMV) is very high worldwide (1,2). 
Spectrum of disease by CMV ranges from asymptomatic state or a mononucleosis-like 
syndrome to severe disease including pneumonia, retinitis or gastrointestinal infection. 
The most severe disease occurs in congenital infection and in immunosuppressed 
patients, in whom the virus act as an opportunistic pathogen.  
Its role in other populations is less clear and controversial (3). Some studies in critical 
patients describe a relation between CMV and increase mortality rates, longer length 
of stay and prolonged needed of mechanical ventilation (3, 4, 5).  The incidence of 
active CMV infection depends on the diagnostic method used. Using the most 
sophisticated available biological tools, the incidence can reach 15–20 % of (intensive 
care unit) ICU patients (6). We aimed to assess the incidence, clinical characteristics, 
risk factors, and outcomes of ICU patients with CMV detection in BAL. 
We performed a prospective observational cohort study of consecutive adult patients 
admitted to two ICUs within 24 hours of admission to the Emergency Department. This 
study has been conducted at Hospital Clínic of Barcelona, Barcelona, Spain, between 
January 2013 and November 2015. Inclusion criteria were: 1) ICU admitted patients, 2) 
Practice of BAL. The decision of performing bronchoscopy was made by the attending 
physicians. Due to the nature of the study, the researchers had no impact in this 
decision.  
The following parameters were recorded at admission: demographic, co-morbidities, 
immunodepressed status, antibiotic treatment in the previous 30 days before hospital 
admission, treatment with oral and inhaled corticosteroids, clinical symptoms, 
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laboratory parameters, diagnostic procedures, ventilatory support, length of hospital 
stay, length of ICU stay, and 30-day mortality. Immunosuppression was defined as 
presence of solid organ or bone marrow transplantation, human immunodeficiency 
virus (HIV) infection, cancer under chemotherapy, and/or treatment with 
corticosteroids (daily doses >20 mg prednisolone-equivalent for more than two 
weeks). Sepsis-related organ failure assessment (SOFA) score was calculated at ICU 
admission (7). BAL were cultured for bacteria, fungi and mycobacteria. One hundred 
microliters of BAL were inoculated onto sheep blood, chocolate, blood charcoal yeast 
extract (BCYE) and Sabouraud agar. All cultures were incubated at 37°C under aerobic 
conditions and in CO2-enriched atmosphere, except for Sabouraud agar that was 
incubated at 25ºC. Cultures were evaluated for growth 24h and 48h later and 
discarded if negative. Bacterial identification and antibiotic susceptibility tests were 
performed according EUCAST guidelines and breakpoints (version 5.0, 2015; 
http://www.eucast.org). Pneumocystis jirovecii was detected by 
methenamine silver stain. For the detection of herpes simplex virus 1 (HSV-1) and 2 
(HSV-2) on BAL, we used human fibroblast cells monitored for up to 1 week for sign of 
infection. A BAL was considered positive when a cytopathic effect was observed on 
conventional cell cultures and then confirmed by inmunofluoresce detection of the 
antigen. Molecular detection of CMV in BAL and blood was performed by real-time 
quantitative PCR (ELITechGroup, Italy), after extraction of DNA with DSP 
Virus/Pathogen Midi kit (Hilden, Germany) on a QIAsymphony automated platform 
(Qiagen, Germany). This technique has a detection limit of 20 copies/mL and a 
quantitative limit of 282 copies/mL. Other respiratory virus were detected by two 
multiplex reverse transcription nested-PCR assays as previously described (8). 
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We report the number and percentage of patients for categorical variables and the 
median (interquartile range [IQR]) for continuous. Categorical variables were 
compared using the χ
2
 or the Fisher exact test. Continuous variables were compared 
using the Mann-Whitney test. Logistic regression analyses were performed to identify 
variables associated with positive detection of CMV; variables that showed a p<0.20 in 
the univariate analyses were included in the multivariate model (backward stepwise 
procedure). The Hosmer-Lemeshow goodness-of-fit test was performed to assess the 
overall fit of the multivariate model (9). The area under the receiver operating 
characteristic (ROC) curve of the multivariate model to predict positive detection of 
CMV was calculated. Internal validation was conducted using ordinary nonparametric 
bootstrapping with 1,000 bootstrap samples and bias-corrected, accelerated 95% 
confidence intervals (CIs) (10). The level of significance was set at 0.05 (2-tailed). All 
analyses were performed using IBM SPSS Statistics 22.0 (Armonk, New York, USA). 
During the study period 880 patients were admitted to the two ICUs. BAL was practice 
in 133 (15%) patients. The three main causes of ICU admission in these 133 patients 
were: respiratory failure (n=83, 62%), septic shock (n=23, 17%) and cardiac failure 
(n=11, 8%). The main cause for BAL practice was suspected respiratory infection. 
Detection of CMV in BAL sample was positive in 26% (35/133) of the samples, 
corresponding to a 4% (35/880) of the ICU patients, with a median (IQR) of 7,637 
(2604-47249) copies/mL. The detection of CMV was performed in 19 samples of blood 
from patients with CMV in BAL, being positive in 13/19 (68%) cases with a median of 
4,323 (433-2272) copies/mL.  
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In 18/133 (14%) BAL CMV was the only microorganism detected, in 17/133 (13%) CMV 
and other microorganisms, in 49/133 (37%) only other microorganisms different from 
CMV and in 49/133 (37%) no microorganism was detected. Pseudomonas aeruginosa 
(16/133, 12%) was the most frequent microorganism isolated, followed by 
Stenotrophomona maltophilia (8/133, 6%), rhinovirus (7/133, 5.3%) and influenza virus 
A (7/133, 5.3%). Demographics and clinical characteristics are presented in Table 1. 
Patients with CMV had received more previous systemic corticosteroids (49% vs. 21%, 
p=0.002), were more frequently immunosuppressed (71% vs. 48%, p=0.017), had 
longer hospital stay (35 vs. 46 days, p=0.017), and had higher 30-day mortality (64% vs. 
41%, p=0.024). Multivariate logistic regression analysis revealed that previous use of 
corticosteroids (OR 3.46, 95% CI 1.53 to 7.86) was the only risk factor for positive 
detection of CMV. The area under the ROC curve was 0.64 (95% CI 0.52 to 0.75) for the 
predictive model of positive detection of CMV. The only variable included in the model 
demonstrated robust results, with a small 95% CI around the original coefficient. 
What we learned from our study is that the detection of CMV in BAL was positive in 4% 
(35/880) of the ICU patients, which is a lower incidence than previously published (6), 
but it is remarkable that 29% of the patients with CMV detection in BAL were 
immunocompetent.  
Immunosuppression was associated with CMV detection in BAL, at the expense of 
systemic corticosteroid.  
The detection of CMV in BAL was associated to a longer hospital stay and higher 
mortality, as describe previously (3, 11). The mechanism that could explain it is 
complex: direct CMV pathogenicity (12) or indirect CMV effects (13), such as CMV 
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mediated inmunosuppression (14) and CMV-mediated lung injury. ICU stay length was 
longer in the group of patients with CMV but not statistically significant, probably 
because of the sample number. 
All of these studies are observational, which leads us to the question of whether there 
is a causal relationship between CMV infection and unfavourable outcomes. However, 
some studies show that treatment with ganciclovir or foscarnet have improved the 
outcome in UCI patients with CMV pneumonia (15).  
Negative associated outcomes suggest that detection screening for CMV would be 
necessary in all patients with suspicion of respiratory infection in ICU. Additional 
prospective trials are necessary to confirm this hypothesis. 
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16. Table 1. Baseline characteristics and clinical outcomes depending on the CMV 
PCR result. 
Variable Negative CMV 
(n=98) 
Positive CMV 
(n=35) 
p-Value 
Demographic    
    Age, median (IQR), years 62.0 (23.0) 61.0 (24.0) 0.37 
    Men, n (%) 63 (64) 23 (66) 0.88 
    Current smoker, n (%) 31 (36) 7 (25) 0.28 
    Current alcohol consumer, n (%) 8 (10) 2 (7) >0.99 
Immunocompromised, n (%)
a
 
   HIV 
   Transplant 
   Cancer 
   Systemic corticosteroid
b
 
47 (48) 
8 (8) 
19 (19) 
16 (16) 
21 (21) 
25 (71) 
3 (9) 
9 (26) 
7 (20) 
17 (49) 
0.017 
>0.99 
0.43 
0.62 
0.002 
Diagnosis at ICU admission 
   Respiratory failure 
   Septic shock 
   Cardiac failure 
   Sepsis  
   Other  
 
59 (60) 
18 (18) 
9 (9) 
5 (5) 
7 (7) 
 
24 (69) 
5 (14) 
2 (6) 
1 (3) 
3 (9) 
0.73 
Previous antibiotic, n (%) 7 (7) 3 (9) 0.72 
Comorbidities, n (%)
c
 76 (78) 26 (74) 0.70 
    Chronic respiratory disease 27 (28) 8 (23) 0.55 
    Chronic cardiovascular disease 23 (24) 6 (17) 0.44 
    Diabetes mellitus 12 (12) 6 (17) 0.57 
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Variable Negative CMV 
(n=98) 
Positive CMV 
(n=35) 
p-Value 
    Neurological disease 11 (11) 7 (20) 0.25 
    Chronic renal disease 12 (12) 7 (20) 0.27 
    Chronic liver disease 4 (4) 2 (6) 0.65 
    Arterial hypertension 38 (39) 18 (51) 0.19 
Laboratory tests, median (IQR)    
    Creatinine, mg/mL  1.0 (1.0) 1.2 (1.1) 0.98 
    C-reactive protein, mg/dL 12.5 (15.9) 11.9 (20.0) 0.87 
    White blood cell count, 10
9
/L 10.0 (9.0) 9.0 (12.0) 0.41 
SOFA score (ICU admission), median 
(IQR) 
5 (6) 5 (5) 
0.91 
 
Outcomes    
    Pulmonary complications, n (%) 16 (39) 5 (33) 0.70 
    NIMV, n (%) 59 (94) 17 (94) >0.99 
    IMV, n (%) 72 (92) 26 (93) >0.99 
    Hospital stay days, median (IQR) 35.0 (33.0) 46.0 (62.0) 0.017 
    ICU stay days, median (IQR) 19.5 (21.5) 31.5 (69.0) 0.070 
    30-day mortality, n (%) 38 (41) 21 (64) 0.024 
17. BAL: bronchoalveolar lavage; HIV: human immunodeficiency virus;ICU: 
intensive unit care; IMV: invasive mechanical ventilation; IQR: interquartile 
range; NIMV: non-invasive mechanical ventilation. 
a
 Could have more than 1 
immunodeficiency condition. 
b
 Daily doses >20 mg prednisolone-equivalent for 
more than two weeks. 
c
Could have more than 1 comorbid condition. 
18.  
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